



Tuberculosis Drugs Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-22	137	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Tuberculosis Drugs market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Tuberculosis Drugs is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Tuberculosis Drugs is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Tuberculosis Drugs is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Tuberculosis Drugs include Abbott, Teva Pharmaceutical Industries Ltd, Sanofi, Johnson & Johnson, Novartis AG, Eli Lilly and Company, Pfizer Inc, AstraZeneca Plc and Viatris Inc. (Mylan N.V.), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Tuberculosis Drugs market in terms of revenue (US\$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tuberculosis Drugs Market by Company

Abbott

Teva Pharmaceutical Industries Ltd

Sanofi

Johnson & Johnson

Novartis AG

Eli Lilly and Company

Pfizer Inc

AstraZeneca Plc

Viatis Inc. (Mylan N.V.)

Sun Pharmaceutical Industries Ltd.

Otsuka Pharmaceutical

Macleods Pharmaceuticals Ltd.

Lupin Laboratories Ltd

FRESENIUS SE & Co. KGaA (Fresenius Kabi)

Cipla Ltd

Cadila Pharmaceuticals

ANI Pharmaceuticals, Inc

Alkem Laboratories Ltd

Tuberculosis Drugs Segment by Type

First Line Drugs Therapy

Combination Drugs Therapy

Second Line Drugs Therapy

Tuberculosis Drugs Segment by Application

Hospital

Private Clinic

Others

Tuberculosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Tuberculosis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Tuberculosis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Tuberculosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Tuberculosis Drugs Market Size (2021-2032)
 - 2.2.2 Global Tuberculosis Drugs Sales (2021-2032)
 - 2.2.3 Global Tuberculosis Drugs Market Average Price (2021-2032)
- 2.3 Tuberculosis Drugs by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 First Line Drugs Therapy
 - 2.3.3 Combination Drugs Therapy
 - 2.3.4 Second Line Drugs Therapy
- 2.4 Tuberculosis Drugs by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Hospital
 - 2.4.3 Private Clinic
 - 2.4.4 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Tuberculosis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tuberculosis Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Tuberculosis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Tuberculosis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Tuberculosis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tuberculosis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tuberculosis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Tuberculosis Drugs, Established Date
- 3.9 Global Tuberculosis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Abbott
 - 4.1.1 Abbott Company Information
 - 4.1.2 Abbott Business Overview
 - 4.1.3 Abbott Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 Abbott Tuberculosis Drugs Product Portfolio
 - 4.1.5 Abbott Recent Developments
- 4.2 Teva Pharmaceutical Industries Ltd

4.2.1 Teva Pharmaceutical Industries Ltd Company Information

4.2.2 Teva Pharmaceutical Industries Ltd Business Overview

4.2.3 Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)

4.2.4 Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Product Portfolio

4.2.5 Teva Pharmaceutical Industries Ltd Recent Developments

4.3 Sanofi

4.3.1 Sanofi Company Information

4.3.2 Sanofi Business Overview

4.3.3 Sanofi Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)

4.3.4 Sanofi Tuberculosis Drugs Product Portfolio

4.3.5 Sanofi Recent Developments

4.4 Johnson & Johnson

4.4.1 Johnson & Johnson Company Information

4.4.2 Johnson & Johnson Business Overview

4.4.3 Johnson & Johnson Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)

4.4.4 Johnson & Johnson Tuberculosis Drugs Product Portfolio

4.4.5 Johnson & Johnson Recent Developments

4.5 Novartis AG

4.5.1 Novartis AG Company Information

4.5.2 Novartis AG Business Overview

4.5.3 Novartis AG Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)

4.5.4 Novartis AG Tuberculosis Drugs Product Portfolio

4.5.5 Novartis AG Recent Developments

4.6 Eli Lilly and Company

4.6.1 Eli Lilly and Company Company Information

4.6.2 Eli Lilly and Company Business Overview

4.6.3 Eli Lilly and Company Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)

4.6.4 Eli Lilly and Company Tuberculosis Drugs Product Portfolio

4.6.5 Eli Lilly and Company Recent Developments

4.7 Pfizer Inc

4.7.1 Pfizer Inc Company Information

4.7.2 Pfizer Inc Business Overview

4.7.3 Pfizer Inc Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)

4.7.4 Pfizer Inc Tuberculosis Drugs Product Portfolio

4.7.5 Pfizer Inc Recent Developments

4.8 AstraZeneca Plc

4.8.1 AstraZeneca Plc Company Information

4.8.2 AstraZeneca Plc Business Overview

4.8.3 AstraZeneca Plc Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)

4.8.4 AstraZeneca Plc Tuberculosis Drugs Product Portfolio

4.8.5 AstraZeneca Plc Recent Developments

4.9 Viatris Inc. (Mylan N.V.)

4.9.1 Viatris Inc. (Mylan N.V.) Company Information

4.9.2 Viatris Inc. (Mylan N.V.) Business Overview

4.9.3 Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)

4.9.4 Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Product Portfolio

4.9.5 Viatris Inc. (Mylan N.V.) Recent Developments

4.10 Sun Pharmaceutical Industries Ltd.

- 4.10.1 Sun Pharmaceutical Industries Ltd. Company Information
- 4.10.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 4.10.3 Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Product Portfolio
- 4.10.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 4.11 Otsuka Pharmaceutical
 - 4.11.1 Otsuka Pharmaceutical Company Information
 - 4.11.2 Otsuka Pharmaceutical Business Overview
 - 4.11.3 Otsuka Pharmaceutical Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.11.4 Otsuka Pharmaceutical Tuberculosis Drugs Product Portfolio
 - 4.11.5 Otsuka Pharmaceutical Recent Developments
- 4.12 Macleods Pharmaceuticals Ltd.
 - 4.12.1 Macleods Pharmaceuticals Ltd. Company Information
 - 4.12.2 Macleods Pharmaceuticals Ltd. Business Overview
 - 4.12.3 Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.12.4 Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Product Portfolio
 - 4.12.5 Macleods Pharmaceuticals Ltd. Recent Developments
- 4.13 Lupin Laboratories Ltd
 - 4.13.1 Lupin Laboratories Ltd Company Information
 - 4.13.2 Lupin Laboratories Ltd Business Overview
 - 4.13.3 Lupin Laboratories Ltd Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.13.4 Lupin Laboratories Ltd Tuberculosis Drugs Product Portfolio
 - 4.13.5 Lupin Laboratories Ltd Recent Developments
- 4.14 FRESENIUS SE & Co. KGaA (Fresenius Kabi)
 - 4.14.1 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Company Information
 - 4.14.2 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Business Overview
 - 4.14.3 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.14.4 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Product Portfolio
 - 4.14.5 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Recent Developments
- 4.15 Cipla Ltd
 - 4.15.1 Cipla Ltd Company Information
 - 4.15.2 Cipla Ltd Business Overview
 - 4.15.3 Cipla Ltd Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.15.4 Cipla Ltd Tuberculosis Drugs Product Portfolio
 - 4.15.5 Cipla Ltd Recent Developments
- 4.16 Cadila Pharmaceuticals
 - 4.16.1 Cadila Pharmaceuticals Company Information
 - 4.16.2 Cadila Pharmaceuticals Business Overview
 - 4.16.3 Cadila Pharmaceuticals Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.16.4 Cadila Pharmaceuticals Tuberculosis Drugs Product Portfolio
 - 4.16.5 Cadila Pharmaceuticals Recent Developments
- 4.17 ANI Pharmaceuticals, Inc
 - 4.17.1 ANI Pharmaceuticals, Inc Company Information
 - 4.17.2 ANI Pharmaceuticals, Inc Business Overview
 - 4.17.3 ANI Pharmaceuticals, Inc Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.17.4 ANI Pharmaceuticals, Inc Tuberculosis Drugs Product Portfolio
 - 4.17.5 ANI Pharmaceuticals, Inc Recent Developments
- 4.18 Alkem Laboratories Ltd

- 4.18.1 Alkem Laboratories Ltd Company Information
- 4.18.2 Alkem Laboratories Ltd Business Overview
- 4.18.3 Alkem Laboratories Ltd Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Alkem Laboratories Ltd Tuberculosis Drugs Product Portfolio
- 4.18.5 Alkem Laboratories Ltd Recent Developments

5 Global Tuberculosis Drugs Market Scenario by Region

- 5.1 Global Tuberculosis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Tuberculosis Drugs Sales by Region: 2021-2032
 - 5.2.1 Global Tuberculosis Drugs Sales by Region: 2021-2026
 - 5.2.2 Global Tuberculosis Drugs Sales by Region: 2027-2032
- 5.3 Global Tuberculosis Drugs Revenue by Region: 2021-2032
 - 5.3.1 Global Tuberculosis Drugs Revenue by Region: 2021-2026
 - 5.3.2 Global Tuberculosis Drugs Revenue by Region: 2027-2032
- 5.4 North America Tuberculosis Drugs Market Facts & Figures by Country
 - 5.4.1 North America Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Tuberculosis Drugs Sales by Country (2021-2032)
 - 5.4.3 North America Tuberculosis Drugs Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
- 5.5 Europe Tuberculosis Drugs Market Facts & Figures by Country
 - 5.5.1 Europe Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe Tuberculosis Drugs Sales by Country (2021-2032)
 - 5.5.3 Europe Tuberculosis Drugs Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Russia
 - 5.5.9 Spain
 - 5.5.10 Netherlands
 - 5.5.11 Switzerland
 - 5.5.12 Sweden
 - 5.5.13 Poland
- 5.6 Asia Pacific Tuberculosis Drugs Market Facts & Figures by Country
 - 5.6.1 Asia Pacific Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific Tuberculosis Drugs Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific Tuberculosis Drugs Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 Taiwan
 - 5.6.10 Southeast Asia
- 5.7 South America Tuberculosis Drugs Market Facts & Figures by Country
 - 5.7.1 South America Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America Tuberculosis Drugs Sales by Country (2021-2032)

5.7.3 South America Tuberculosis Drugs Revenue by Country (2021-2032)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Tuberculosis Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Tuberculosis Drugs Sales by Country (2021-2032)
5.8.3 Middle East and Africa Tuberculosis Drugs Revenue by Country (2021-2032)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries

6 Segment by Type

6.1 Global Tuberculosis Drugs Sales by Type (2021-2032)
6.1.1 Global Tuberculosis Drugs Sales by Type (2021-2032) & (k units)
6.1.2 Global Tuberculosis Drugs Sales Market Share by Type (2021-2032)
6.2 Global Tuberculosis Drugs Revenue by Type (2021-2032)
6.2.1 Global Tuberculosis Drugs Sales by Type (2021-2032) & (US\$ Million)
6.2.2 Global Tuberculosis Drugs Revenue Market Share by Type (2021-2032)
6.3 Global Tuberculosis Drugs Price by Type (2021-2032)

7 Segment by Application

7.1 Global Tuberculosis Drugs Sales by Application (2021-2032)
7.1.1 Global Tuberculosis Drugs Sales by Application (2021-2032) & (k units)
7.1.2 Global Tuberculosis Drugs Sales Market Share by Application (2021-2032)
7.2 Global Tuberculosis Drugs Revenue by Application (2021-2032)
7.2.1 Global Tuberculosis Drugs Sales by Application (2021-2032) & (US\$ Million)
7.2.2 Global Tuberculosis Drugs Revenue Market Share by Application (2021-2032)
7.3 Global Tuberculosis Drugs Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Tuberculosis Drugs Value Chain Analysis
8.1.1 Tuberculosis Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Tuberculosis Drugs Production Mode & Process
8.2 Tuberculosis Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Tuberculosis Drugs Distributors
8.2.3 Tuberculosis Drugs Customers

9 Global Tuberculosis Drugs Analyzing Market Dynamics

9.1 Tuberculosis Drugs Industry Trends
9.2 Tuberculosis Drugs Industry Drivers
9.3 Tuberculosis Drugs Industry Opportunities and Challenges
9.4 Tuberculosis Drugs Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Tuberculosis Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Tuberculosis Drugs Sales (k units) of Manufacturers (2021-2026)
- Table 7: Global Tuberculosis Drugs Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Tuberculosis Drugs Revenue of Manufacturers (2021-2026)
- Table 9: Global Tuberculosis Drugs Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Tuberculosis Drugs Average Price (US\$/unit) of Manufacturers (2021-2026)
- Table 11: Global Tuberculosis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Tuberculosis Drugs, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Tuberculosis Drugs, Product Type & Application
- Table 14: Global Tuberculosis Drugs Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Tuberculosis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Abbott Company Information
- Table 19: Abbott Business Overview
- Table 20: Abbott Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 21: Abbott Tuberculosis Drugs Product Portfolio
- Table 22: Abbott Recent Developments
- Table 23: Teva Pharmaceutical Industries Ltd Company Information
- Table 24: Teva Pharmaceutical Industries Ltd Business Overview
- Table 25: Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 26: Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Product Portfolio
- Table 27: Teva Pharmaceutical Industries Ltd Recent Developments
- Table 28: Sanofi Company Information
- Table 29: Sanofi Business Overview
- Table 30: Sanofi Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 31: Sanofi Tuberculosis Drugs Product Portfolio
- Table 32: Sanofi Recent Developments
- Table 33: Johnson & Johnson Company Information
- Table 34: Johnson & Johnson Business Overview
- Table 35: Johnson & Johnson Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 36: Johnson & Johnson Tuberculosis Drugs Product Portfolio
- Table 37: Johnson & Johnson Recent Developments
- Table 38: Novartis AG Company Information
- Table 39: Novartis AG Business Overview
- Table 40: Novartis AG Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 41: Novartis AG Tuberculosis Drugs Product Portfolio
- Table 42: Novartis AG Recent Developments
- Table 43: Eli Lilly and Company Company Information
- Table 44: Eli Lilly and Company Business Overview
- Table 45: Eli Lilly and Company Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 46: Eli Lilly and Company Tuberculosis Drugs Product Portfolio
- Table 47: Eli Lilly and Company Recent Developments
- Table 48: Pfizer Inc Company Information
- Table 49: Pfizer Inc Business Overview
- Table 50: Pfizer Inc Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)

- Table 51: Pfizer Inc Tuberculosis Drugs Product Portfolio
- Table 52: Pfizer Inc Recent Developments
- Table 53: AstraZeneca Plc Company Information
- Table 54: AstraZeneca Plc Business Overview
- Table 55: AstraZeneca Plc Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 56: AstraZeneca Plc Tuberculosis Drugs Product Portfolio
- Table 57: AstraZeneca Plc Recent Developments
- Table 58: Viatris Inc. (Mylan N.V.) Company Information
- Table 59: Viatris Inc. (Mylan N.V.) Business Overview
- Table 60: Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 61: Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Product Portfolio
- Table 62: Viatris Inc. (Mylan N.V.) Recent Developments
- Table 63: Sun Pharmaceutical Industries Ltd. Company Information
- Table 64: Sun Pharmaceutical Industries Ltd. Business Overview
- Table 65: Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 66: Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Product Portfolio
- Table 67: Sun Pharmaceutical Industries Ltd. Recent Developments
- Table 68: Otsuka Pharmaceutical Company Information
- Table 69: Otsuka Pharmaceutical Business Overview
- Table 70: Otsuka Pharmaceutical Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 71: Otsuka Pharmaceutical Tuberculosis Drugs Product Portfolio
- Table 72: Otsuka Pharmaceutical Recent Developments
- Table 73: Macleods Pharmaceuticals Ltd. Company Information
- Table 74: Macleods Pharmaceuticals Ltd. Business Overview
- Table 75: Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 76: Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Product Portfolio
- Table 77: Macleods Pharmaceuticals Ltd. Recent Developments
- Table 78: Lupin Laboratories Ltd Company Information
- Table 79: Lupin Laboratories Ltd Business Overview
- Table 80: Lupin Laboratories Ltd Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 81: Lupin Laboratories Ltd Tuberculosis Drugs Product Portfolio
- Table 82: Lupin Laboratories Ltd Recent Developments
- Table 83: FRESENIUS SE & Co. KGaA (Fresenius Kabi) Company Information
- Table 84: FRESENIUS SE & Co. KGaA (Fresenius Kabi) Business Overview
- Table 85: FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 86: FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Product Portfolio
- Table 87: FRESENIUS SE & Co. KGaA (Fresenius Kabi) Recent Developments
- Table 88: Cipla Ltd Company Information
- Table 89: Cipla Ltd Business Overview
- Table 90: Cipla Ltd Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 91: Cipla Ltd Tuberculosis Drugs Product Portfolio
- Table 92: Cipla Ltd Recent Developments
- Table 93: Cadila Pharmaceuticals Company Information
- Table 94: Cadila Pharmaceuticals Business Overview
- Table 95: Cadila Pharmaceuticals Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 96: Cadila Pharmaceuticals Tuberculosis Drugs Product Portfolio
- Table 97: Cadila Pharmaceuticals Recent Developments
- Table 98: ANI Pharmaceuticals, Inc Company Information
- Table 99: ANI Pharmaceuticals, Inc Business Overview
- Table 100: ANI Pharmaceuticals, Inc Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 101: ANI Pharmaceuticals, Inc Tuberculosis Drugs Product Portfolio
- Table 102: ANI Pharmaceuticals, Inc Recent Developments
- Table 103: Alkem Laboratories Ltd Company Information
- Table 104: Alkem Laboratories Ltd Business Overview
- Table 105: Alkem Laboratories Ltd Tuberculosis Drugs Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)

- Table 106: Alkem Laboratories Ltd Tuberculosis Drugs Product Portfolio
- Table 107: Alkem Laboratories Ltd Recent Developments
- Table 108: Global Tuberculosis Drugs Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 109: Global Tuberculosis Drugs Sales by Region (2021-2026) & (k units)
- Table 110: Global Tuberculosis Drugs Sales Market Share by Region (2021-2026)
- Table 111: Global Tuberculosis Drugs Sales by Region (2027-2032) & (k units)
- Table 112: Global Tuberculosis Drugs Sales Market Share by Region (2027-2032)
- Table 113: Global Tuberculosis Drugs Revenue by Region (2021-2026) & (US\$ Million)
- Table 114: Global Tuberculosis Drugs Revenue Market Share by Region (2021-2026)
- Table 115: Global Tuberculosis Drugs Revenue by Region (2027-2032) & (US\$ Million)
- Table 116: Global Tuberculosis Drugs Revenue Market Share by Region (2027-2032)
- Table 117: North America Tuberculosis Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 118: North America Tuberculosis Drugs Sales by Country (2021-2026) & (k units)
- Table 119: North America Tuberculosis Drugs Sales by Country (2027-2032) & (k units)
- Table 120: North America Tuberculosis Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 121: North America Tuberculosis Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 122: Europe Tuberculosis Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 123: Europe Tuberculosis Drugs Sales by Country (2021-2026) & (k units)
- Table 124: Europe Tuberculosis Drugs Sales by Country (2027-2032) & (k units)
- Table 125: Europe Tuberculosis Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 126: Europe Tuberculosis Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 127: Asia Pacific Tuberculosis Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 128: Asia Pacific Tuberculosis Drugs Sales by Country (2021-2026) & (k units)
- Table 129: Asia Pacific Tuberculosis Drugs Sales by Country (2027-2032) & (k units)
- Table 130: Asia Pacific Tuberculosis Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 131: Asia Pacific Tuberculosis Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 132: South America Tuberculosis Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 133: South America Tuberculosis Drugs Sales by Country (2021-2026) & (k units)
- Table 134: South America Tuberculosis Drugs Sales by Country (2027-2032) & (k units)
- Table 135: South America Tuberculosis Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 136: South America Tuberculosis Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 137: Middle East and Africa Tuberculosis Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 138: Middle East and Africa Tuberculosis Drugs Sales by Country (2021-2026) & (k units)
- Table 139: Middle East and Africa Tuberculosis Drugs Sales by Country (2027-2032) & (k units)
- Table 140: Middle East and Africa Tuberculosis Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 141: Middle East and Africa Tuberculosis Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 142: Global Tuberculosis Drugs Sales by Type (2021-2026) & (k units)
- Table 143: Global Tuberculosis Drugs Sales by Type (2027-2032) & (k units)
- Table 144: Global Tuberculosis Drugs Sales Market Share by Type (2021-2026)
- Table 145: Global Tuberculosis Drugs Sales Market Share by Type (2027-2032)
- Table 146: Global Tuberculosis Drugs Revenue by Type (2021-2026) & (US\$ Million)
- Table 147: Global Tuberculosis Drugs Revenue by Type (2027-2032) & (US\$ Million)
- Table 148: Global Tuberculosis Drugs Revenue Market Share by Type (2021-2026)
- Table 149: Global Tuberculosis Drugs Revenue Market Share by Type (2027-2032)
- Table 150: Global Tuberculosis Drugs Price by Type (2021-2026) & (US\$/unit)
- Table 151: Global Tuberculosis Drugs Price by Type (2027-2032) & (US\$/unit)
- Table 152: Global Tuberculosis Drugs Sales by Application (2021-2026) & (k units)
- Table 153: Global Tuberculosis Drugs Sales by Application (2027-2032) & (k units)
- Table 154: Global Tuberculosis Drugs Sales Market Share by Application (2021-2026)
- Table 155: Global Tuberculosis Drugs Sales Market Share by Application (2027-2032)
- Table 156: Global Tuberculosis Drugs Revenue by Application (2021-2026) & (US\$ Million)
- Table 157: Global Tuberculosis Drugs Revenue by Application (2027-2032) & (US\$ Million)
- Table 158: Global Tuberculosis Drugs Revenue Market Share by Application (2021-2026)
- Table 159: Global Tuberculosis Drugs Revenue Market Share by Application (2027-2032)
- Table 160: Global Tuberculosis Drugs Price by Application (2021-2026) & (US\$/unit)
- Table 161: Global Tuberculosis Drugs Price by Application (2027-2032) & (US\$/unit)
- Table 162: Key Raw Materials
- Table 163: Raw Materials Key Suppliers
- Table 164: Tuberculosis Drugs Distributors List
- Table 165: Tuberculosis Drugs Customers List
- Table 166: Tuberculosis Drugs Industry Trends
- Table 167: Tuberculosis Drugs Industry Drivers
- Table 168: Tuberculosis Drugs Industry Restraints
- Table 169: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Tuberculosis Drugs Product Image
- Figure 5: Global Tuberculosis Drugs Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Tuberculosis Drugs Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Tuberculosis Drugs Sales (2021-2032) & (k units)
- Figure 8: Global Tuberculosis Drugs Average Price (US\$/unit) & (2021-2032)
- Figure 9: First Line Drugs Therapy Product Image
- Figure 10: Combination Drugs Therapy Product Image
- Figure 11: Second Line Drugs Therapy Product Image
- Figure 12: Hospital Product Image
- Figure 13: Private Clinic Product Image
- Figure 14: Others Product Image
- Figure 15: Global Tuberculosis Drugs Revenue Share by Manufacturers in 2025
- Figure 16: Global Manufacturers of Tuberculosis Drugs, Manufacturing Sites & Headquarters
- Figure 17: Global Top 5 and 10 Tuberculosis Drugs Players Market Share by Revenue in 2025
- Figure 18: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 19: Global Tuberculosis Drugs Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 20: Global Tuberculosis Drugs Sales by Region in 2025
- Figure 21: Global Tuberculosis Drugs Revenue by Region in 2025
- Figure 22: North America Tuberculosis Drugs Market Size by Country in 2025
- Figure 23: North America Tuberculosis Drugs Sales Market Share by Country (2021-2032)
- Figure 24: North America Tuberculosis Drugs Revenue Market Share by Country (2021-2032)
- Figure 25: United States Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 26: Canada Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Mexico Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Europe Tuberculosis Drugs Market Size by Country in 2025
- Figure 29: Europe Tuberculosis Drugs Sales Market Share by Country (2021-2032)
- Figure 30: Europe Tuberculosis Drugs Revenue Market Share by Country (2021-2032)
- Figure 31: Germany Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: France Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: U.K. Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: Italy Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Russia Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Spain Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Netherlands Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Switzerland Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Sweden Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Poland Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Asia Pacific Tuberculosis Drugs Market Size by Country in 2025
- Figure 42: Asia Pacific Tuberculosis Drugs Sales Market Share by Country (2021-2032)
- Figure 43: Asia Pacific Tuberculosis Drugs Revenue Market Share by Country (2021-2032)
- Figure 44: China Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: Japan Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: South Korea Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: India Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Australia Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Taiwan Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Southeast Asia Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Southeast Asia Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: South America Tuberculosis Drugs Market Size by Country in 2025
- Figure 53: South America Tuberculosis Drugs Sales Market Share by Country (2021-2032)
- Figure 54: South America Tuberculosis Drugs Revenue Market Share by Country (2021-2032)
- Figure 55: Brazil Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: Argentina Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Chile Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Middle East and Africa Tuberculosis Drugs Market Size by Country in 2025
- Figure 59: Middle East and Africa Tuberculosis Drugs Sales Market Share by Country (2021-2032)
- Figure 60: Middle East and Africa Tuberculosis Drugs Revenue Market Share by Country (2021-2032)
- Figure 61: Egypt Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 62: South Africa Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 63: Israel Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: Türkiye Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: GCC Countries Tuberculosis Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: Global Tuberculosis Drugs Sales Market Share by Type (2021-2032)
- Figure 67: Global Tuberculosis Drugs Revenue Market Share by Type (2021-2032)
- Figure 68: Global Tuberculosis Drugs Price (US\$/unit) by Type (2021-2032)
- Figure 69: Global Tuberculosis Drugs Sales Market Share by Application (2021-2032)
- Figure 70: Global Tuberculosis Drugs Revenue Market Share by Application (2021-2032)
- Figure 71: Global Tuberculosis Drugs Price (US\$/unit) by Application (2021-2032)
- Figure 72: Tuberculosis Drugs Value Chain
- Figure 73: Tuberculosis Drugs Production Mode & Process
- Figure 74: Direct Comparison with Distribution Share
- Figure 75: Distributors Profiles
- Figure 76: Tuberculosis Drugs Industry Opportunities and Challenges